Andras Heczey

3.4k total citations · 2 hit papers
49 papers, 2.1k citations indexed

About

Andras Heczey is a scholar working on Oncology, Neurology and Immunology. According to data from OpenAlex, Andras Heczey has authored 49 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 17 papers in Neurology and 13 papers in Immunology. Recurrent topics in Andras Heczey's work include CAR-T cell therapy research (20 papers), Neuroblastoma Research and Treatments (17 papers) and Immune Cell Function and Interaction (11 papers). Andras Heczey is often cited by papers focused on CAR-T cell therapy research (20 papers), Neuroblastoma Research and Treatments (17 papers) and Immune Cell Function and Interaction (11 papers). Andras Heczey collaborates with scholars based in United States, Ireland and Thailand. Andras Heczey's co-authors include Gianpietro Dotti, Leonid S. Metelitsa, Amy N. Courtney, Linjie Guo, Daofeng Liu, Ekaterina Marinova, Hao Liu, Barbara Savoldo, Chrystal U. Louis and Xiuhua Gao and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Andras Heczey

44 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

2017 391 citations Andras Heczey, Chrystal U. Louis et al. Molecular Therapy profile →
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

2025 14 citations Sandhya Sharma, Andras Heczey et al. Nature Medicine profile →

Peers

Countries citing papers authored by Andras Heczey

Since Specialization

Citations

This map shows the geographic impact of Andras Heczey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andras Heczey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andras Heczey more than expected).

Fields of papers citing papers by Andras Heczey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andras Heczey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andras Heczey. The network helps show where Andras Heczey may publish in the future.

Co-authorship network of co-authors of Andras Heczey

This figure shows the co-authorship network connecting the top 25 collaborators of Andras Heczey. A scholar is included among the top collaborators of Andras Heczey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andras Heczey. Andras Heczey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma breakdown → 2025 ·Nature Medicine ·(unknown), Sandhya Sharma, Andras Heczey, Mae Woods, (unknown), Chrystal U. Louis, Bambi Grilley, Sachin G. Thakkar, Meng-Fen Wu, Tao Wang, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop	14
2	Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors 2025 ·Pediatric Blood & Cancer ·(unknown), Kriti Puri, (unknown), Luci Corrêa, (unknown), Brian D. Friend, Shoba A. Navai, Nabil Ahmed, Meenakshi Hegde, Bilal Omer, Andras Heczey, (unknown), (unknown), Rayne H. Rouce, (unknown), Robert A. Krance, Nino Rainusso, (unknown)	0
3	Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors 2024 ·Cytotherapy ·(unknown), (unknown), Tao Wang, Meng‐Fen Wu, (unknown), Thomas Pfeiffer, Shoba A. Navai, Andras Heczey, Meenakshi Hegde, Nabil Ahmed, Sarah Burkhead Whittle, LaQuisa Hill, Caridad Martinez, Robert A. Krance, Carlos A. Ramos, Rayne H. Rouce, Premal Lulla, Helen E. Heslop, Bilal Omer, (unknown)	0
4	Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population 2023 ·Molecular Therapy ·Tapas Patra, (unknown), Keith Meyer, Károly Tóth, Ratna B. Ray, Andras Heczey, Ranjit Ray	19
5	A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019 2023 ·Pediatric Blood & Cancer ·Kevin Campbell, David A. Siegel, Puja J. Umaretiya, Shifan Dai, Andras Heczey, Philip J. Lupo, Jeremy M. Schraw, Trevor Thompson, Michael E. Scheurer, Jennifer H. Foster	5
6	Integration of a dedicated management protocol in the care of pediatric liver cancer: From specialized providers to complication reduction 2021 ·Journal of Pediatric Surgery ·Richard S. Whitlock, (unknown), Sarah Jane Commander, (unknown), Huirong Zhu, John A. Goss, Kamlesh Kukreja, Daniel H. Leung, (unknown), Prakash Masand, HaiThuy N. Nguyen, Jed G. Nuchtern, David E. Wesson, Andras Heczey, Sanjeev A. Vasudevan	5
7	Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma 2020 ·Cancer Immunology Research ·(unknown), Purva Rathi, Linjie Guo, Amy N. Courtney, Julien Fleurence, Julien Balzeau, Rahamthulla S. Shaik, Thao P. Nguyen, Meng‐Fen Wu, (unknown), Maksim Mamonkin, Leonid S. Metelitsa, Andras Heczey	193
8	Is high‐risk neuroblastoma induction chemotherapy possible without G‐CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors 2020 ·Pediatric Blood & Cancer ·Sarah Burkhead Whittle, Valeria Smith, Allison Silverstein, (unknown), Charles G. Minard, M. Brooke Bernhardt, Peter E. Zage, Rajkumar Venkatramani, Jed G. Nuchtern, Andras Heczey, Heidi V. Russell, Jason M. Shohet, Jennifer H. Foster	3
9	Liver transplant in a recently COVID‐19 positive child with hepatoblastoma 2020 ·Pediatric Transplantation ·(unknown), Flor M. Muñoz, Wenly Ruan, Nhu Thao Nguyen Galván, Christine A. O’Mahony, Abbas Rana, Ronald T. Cotton, Nicolas F. Moreno, Andras Heczey, Daniel H. Leung, John A. Goss	8
10	Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis 2020 ·Nature Medicine ·Andras Heczey, Amy N. Courtney, Antonino Montalbano, Simon N. Robinson, Liu Ka, Mingmei Li, Nisha Ghatwai, Olga Dakhova, Bin Liu, Tali Raveh-Sadka, Cynthia Chauvin, Xin Xu, Ho Ngai, Erica J. Di Pierro, Barbara Savoldo, Gianpietro Dotti, Leonid S. Metelitsa	201
11	NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma 2019 ·Clinical Cancer Research ·Xin Xu, Wei Huang, Andras Heczey, Daofeng Liu, Linjie Guo, Michael S. Wood, Jingling Jin, Amy N. Courtney, Bin Liu, Erica J. Di Pierro, John Hicks, Gabriel A. Barragán, Ho Ngai, Yu‐Hui Chen, Barbara Savoldo, Gianpietro Dotti, Leonid S. Metelitsa	133
12	50 Years Ago in T J P 2018 ·The Journal of Pediatrics ·Xavier Rios, Andras Heczey	1
13	TargetingO-Acetyl-GD2 Ganglioside for Cancer Immunotherapy 2017 ·Journal of Immunology Research ·Julien Fleurence, Sophie Fougeray, (unknown), Denis Cochonneau, Béatrice Clemenceau, François Paris, Andras Heczey, Stéphane Birklé	30
14	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma breakdown → 2017 ·Molecular Therapy ·Andras Heczey, Chrystal U. Louis, Barbara Savoldo, Olga Dakhova, April Durett, Bambi Grilley, Hao Liu, (unknown), Zhuyong Mei, Adrian P. Gee, Birju Mehta, Huimin Zhang, Nadia Mahmood, Haruko Tashiro, Helen E. Heslop, Gianpietro Dotti, Cliona M. Rooney, Malcolm K. Brenner	391
15	T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC 2017 ·Molecular Therapy — Oncolytics ·Árpád Szöőr, Abishek Vaidya, Mireya Paulina Velasquez, Zhuyong Mei, Daniel L. Galvan, David Torres, Adrian P. Gee, Andras Heczey, Stephen Gottschalk	30
16	Vascular invasion is a prognostic indicator in hepatoblastoma 2017 ·Journal of Pediatric Surgery ·Yan Shi, Sarah Jane Commander, Prakash Masand, Andras Heczey, John A. Goss, Sanjeev A. Vasudevan	23
17	Outpatient management of pediatric oncology patients with low-risk fever and neutropenia: Implementation of new clinical practice guideline at Texas Children's Hospital. 2017 ·Journal of Clinical Oncology ·Abhishek Bavle, Amanda B. Grimes, Sibo Zhao, Daniel Zinn, (unknown), (unknown), (unknown), Andras Heczey	0
18	Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups 2016 ·Hepatology ·Pavel Sumazin, Yidong Chen, Lisa R. Treviño, Stephen F. Sarabia, Oliver Hampton, Kayuri Patel, Toni‐Ann Mistretta, Barry Zorman, Patrick Thompson, Andras Heczey, Sarah A. Comerford, David A. Wheeler, Murali Chintagumpala, Rebecka L. Meyers, Dinesh Rakheja, Milton J. Finegold, Gail E. Tomlinson, D. Williams Parsons, Dolores López‐Terrada	142
19	Osteopetrosis and Erlenmeyer-Flask Deformity 2015 ·New England Journal of Medicine ·Andras Heczey, Chrystal U. Louis	3
20	Health disparities are important determinants of outcome for children with solid tumor malignancies 2014 ·Journal of Pediatric Surgery ·Mary T. Austin, Hoang Nguyen, Jan M. Eberth, Yu-Chia Chang, Andras Heczey, Dennis P.M. Hughes, Kevin P. Lally, Linda S. Elting	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact